• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . Predominance of Influenza Virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A Genetic Subclades in the WHO European Region, 2018-2019

tetano

Editor, Senior Moderator
Vaccine


. 2020 Jul 2;S0264-410X(20)30804-5.
doi: 10.1016/j.vaccine.2020.06.031. Online ahead of print.
Predominance of Influenza Virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A Genetic Subclades in the WHO European Region, 2018-2019


Angeliki Melidou[SUP] 1 [/SUP], Olav Hungnes[SUP] 2 [/SUP], Dmitriy Pereyaslov[SUP] 3 [/SUP], Cornelia Adlhoch[SUP] 4 [/SUP], Hannah Segaloff[SUP] 3 [/SUP], Emmanuel Robesyn[SUP] 4 [/SUP], Pasi Penttinen[SUP] 4 [/SUP], Sonja J Olsen[SUP] 3 [/SUP], European Region influenza surveillance network



Affiliations

Abstract

Background: The 2018/2019 influenza season in the WHO European Region was dominated by influenza A (H1N1)pdm09 and (H3N2) viruses, with very few influenza B viruses detected.
Methods: Countries in the European Region reported virus characterization data to The European Surveillance System for weeks 40/2018 to 20/2019. These virus antigenic and genetic characterization and haemagglutinin (HA) sequence data were analysed to describe and assess circulating viruses relative to the 2018/2019 vaccine virus components for the northern hemisphere.
Results: Thirty countries reported 4776 viruses characterized genetically and 3311 viruses antigenically. All genetically characterized A(H1N1)pdm09 viruses fell in subclade 6B.1A, of which 90% carried the amino acid substitution S183P in the HA gene. Antigenic data indicated that circulating A(H1N1)pdm09 viruses were similar to the 2018/2019 vaccine virus. Genetic data showed that A(H3N2) viruses mostly fell in clade 3C.2a (75%) and 90% of which were subclade 3C.2a1b. A lower proportion fell in clade 3C.3a (23%) and were antigenically distinct from the vaccine virus. All B/Victoria viruses belonged to clade 1A; 30% carried a double amino acid deletion in HA and were genetically and antigenically similar to the vaccine virus component, while 55% carried a triple amino acid deletion or no deletion in HA; these were antigenically distinct from each other and from the vaccine component. All B/Yamagata viruses belonged to clade 3 and were antigenically similar to the virus component in the quadrivalent vaccine for 2018/2019.
Conclusions: A simultaneous circulation of genetically and antigenically diverse A(H3N2) and B/Victoria viruses was observed and represented a challenge to vaccine strain selection.

Keywords: Antigenic; Europe; Genetic; Influenza; Surveillance; Vaccine.
 
Back
Top Bottom